大手製薬企業のパートナー契約

Abstract

Report description

The Bigpharma Partnering Agreements provides comprehensive and unprecedented access to the partnering agreements entered into by the worlds leading fifty biopharma companies.

Understanding the flexibility of a prospective partner' s negiotated deals terms provides critical insight into the negotiation process in termsof what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains over 1,200 links to online copies of actual contract documents as submitted to the Securities Exchange Commission by bigpharma and their partners.

Contract documents provide the answers to numerous questions about a prospective partner' s flexibility on a wide range of important issues, many of which will have a significant impact on each party' s ability to derive value from the deal.

The initial chapters of this report provide an orientation of bigpharma' s dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2006 pharmaceutical revenues. Chapter 3 analyses the most active dealmakers in 2005 and 2006 in M&A and partnering deals announced, whilst chapter 4 analyzes the top deals of 2005-6 according to reported deal size.

The main body of the report is provided in chapter 5. Each of the top 50 bigpharma companies is provided with a brief summary followed by a comprehensive listing of contract documents available in the public domain. The listing is sorted by deal type - therefore co-promotion deals are listed separately to licensing, M&A and supply deals, and so on.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Bigpharma - The Top 50

Chapter 3 - Most active bigpharma dealmakers

• 3.1 Bigpharma M&A activity
• 3.2 Bigpharma partnering

Chapter 4 - Top bigpharma deals - 2000-7

• 4.1 Bigpharma M&A
• 4.2 Bigpharma partnering

Chapter 5 - Bigpharma Agreements

• 5.1 How to use bigpharma agreements
• 5.2 What should an agreement contain?
• 5.3 Deal type definitions
• 5.4 Company agreement listings
  • Abbott
  • Actavis
  • Akzo Nobel
  • Allergan
  • Altana
  • Amgen
  • Astellas
  • AstraZeneca
  • Baxter International
  • Bayer
  • Bayer Schering Pharma AG
  • Biogen Idec
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Cephalon
  • Chugai
  • CSL
  • Dainippon Sumitomo
  • Eisai
  • Eli Lilly
  • Forest Laboratories
  • Genentech
  • Genzyme
  • Gilead Sciences
  • GlaxoSmithKline
  • Johnson & Johnson
  • King
  • Lundbeck
  • Menarini
  • Merck & Co
  • Merck - Serono KGaA
  • Mitsubishi
  • Novartis AG
  • Novo Nordisk
  • Nycomed Pharma
  • Otsuka
  • Pfizer
  • Procter & Gamble
  • Roche
  • Sanofi-Aventis
  • Schering Plough
  • Serono
  • Shionogi Seiyaku
  • Shire
  • Solvay
  • Takeda
  • Tanabe Seiyaku
  • TAP Pharmaceuticals
  • Teva
  • UCB
  • Watson
  • Wyeth

Chapter 6 - Resources

Appendices

• Appendix 1 - Example development and license contract document
• Appendix 2 - Example M&A contract document

About CurrentPartnering

Recent report titles from CurrentPartnering

• Order Form - Reports
• Order Form - Report Update Subscription
• Order form - Company Dealmaking Profiles
• Order Form - CD-Rom

Figures in report

• Figure 1: Bigpharma - top 50 by pharma revenues 2006
• Figure 2: Additional bigpharma companies profiled in report
• Figure 3: Leading Bigpharma M&A companies, 2006-7
• Figure 4: Bigpharma-Bigpharma M&A during 2006-7
• Figure 5: Leading Bigpharma partnering companies, 2006-7
• Figure 6: Leading M&A deals by value, 2005-7
• Figure 7: Leading partnering deals by value, 2005-7
• Figure 8: Checklist of key contract agreement clauses in a partnering agreement
• Figure 9: Deal type definitions
• Figure 10: Online partnering resources
• Figure 11: Development and license agreement between Boehringer Ingelheim and Inspire Pharmaceuticals, February 2006
• Figure 12: Agreement and plan of merger between Johnson & Johnson and Guidant Corporation